C. Monzo-Fuentes

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial

R. Greil, H. Hackl, F. Huemer, 2020, Journal of clinical medicine.